Natarajan Muthusamy
Overview
Explore the profile of Natarajan Muthusamy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
4234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jeremy E, Artiga E, Elgamal S, Cheney C, Eicher D, Zalponik K, et al.
Blood Adv
. 2024 Sep;
9(1):1-14.
PMID: 39348689
Acute myeloid leukemia (AML) is the most common and lethal leukemia in adults. AML consists of many genetic subtypes, which limits broad applicability of targeted therapy. We discovered that the...
2.
Nunes J, Tafesse R, Mao C, Purcell M, Mo X, Zhang L, et al.
Nat Commun
. 2024 Jun;
15(1):5180.
PMID: 38890323
Siglec-6 is a lectin receptor with restricted expression in the placenta, mast cells and memory B-cells. Although Siglec-6 is expressed in patients with chronic lymphocytic leukemia (CLL), its pathophysiological role...
3.
Wang L, Leach V, Muthusamy N, Byrd J, Long M
Blood Adv
. 2023 Oct;
8(2):470-481.
PMID: 37871327
T-cell bispecific antibodies (T-BsAbs) such as blinatumomab hold great promise for cancer immunotherapy. A better understanding of the in vivo immune response induced by T-BsAbs is crucial to improving their...
4.
Chan W, Williams J, Sorathia K, Pray B, Abusaleh K, Bian Z, et al.
Exp Hematol Oncol
. 2023 Sep;
12(1):79.
PMID: 37740214
Background: Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma subtype which remains incurable despite multimodal approach including chemoimmunotherapy followed by stem cell transplant, targeted approaches such as the...
5.
Sircar A, Singh S, Xu-Monette Z, Coyle K, Hilton L, Chavdoula E, et al.
Leukemia
. 2023 Aug;
37(10):2094-2106.
PMID: 37598282
Mantle cell lymphoma (MCL) is a lethal hematological malignancy with a median survival of 4 years. Its lethality is mainly attributed to a limited understanding of clinical tumor progression and...
6.
Ayinde O, Sharpe C, Stahl E, Tokarski 2nd R, Lerma J, Muthusamy N, et al.
ACS Med Chem Lett
. 2023 Jul;
14(7):936-942.
PMID: 37465296
Optimization of degrader properties is often a challenge due to their beyond-rule-of-5 nature. Given the paucity of known E3 ligases and the often-limited choice of ligands with varied chemical structures...
7.
Tokarski 2nd R, Sharpe C, Huntsman A, Mize B, Ayinde O, Stahl E, et al.
Eur J Med Chem
. 2023 Apr;
254:115342.
PMID: 37071962
Cyclin-dependent kinase 9 (CDK9) is a promising therapeutic target in multiple cancer types, including acute myeloid leukemia (AML). Protein degraders, also known as proteolysis targeting chimeras (PROTACs), have emerged as...
8.
Yano M, Byrd J, Muthusamy N
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497266
Immunotherapy approaches have advanced rapidly in recent years. While the greatest therapeutic advances so far have been achieved with T cell therapies such as immune checkpoint blockade and CAR-T, recent...
9.
Chiang C, Hu E, Chang L, Labanowska J, Zapolnik K, Mo X, et al.
Cell Rep
. 2022 Jul;
40(3):111115.
PMID: 35858552
The existence of "leukemia-initiating cells" (LICs) in chronic lymphocytic leukemia (CLL) remains controversial due to the difficulty in isolating and identifying the tumor-initiating cells. Here, we demonstrate a microchannel electroporation...
10.
Yano M, Nunes J, Mo X, Rogers K, Woyach J, Byrd J, et al.
Blood Adv
. 2022 Jun;
6(18):5440-5448.
PMID: 35759759
Cytotoxic T lymphocyte antigen 4 (CTLA4) is a major immune checkpoint and target for cancer immunotherapy. Although originally discovered and primarily studied on T cells, its role on other cell...